Discussions with leaders: Kostakoglu talks with Vincent Rajkumar, MD, from the Mayo clinic, about collaborative and pioneering work in establishing influential guidelines in the treatment of myeloma.
Page 831
18F-labeled SSTR tracers: Leupe and colleagues provide an update of currently available clinical data regarding 18F-labeled somatostatin analog tracers and justification for clinical applications.
Page 835
PET/CT and osteosarcoma management: Oh and colleagues offer an educational overview of clinical aspects of osteosarcoma management and assess the role of 18F-FDG PET/CT, with special focus on pediatric and young adult patients.
Page 842
18F-Fluciclovine PET in glioblastoma: Nabavizadeh and colleagues report on a study assessing the value of 18F-fluciclovine PET for differentiating pseudoprogression from tumor progression in patients with suspected radiographic recurrence of glioblastoma.
Page 852
68Ga-DOTA-MGS5 PET/CT in MTC: von Guggenberg and colleagues describe imaging results with this 68Ga-labeled minigastrin analog to evaluate cholecystokinin-2 receptor expression status and local recurrence/metastases in patients with advanced medullary thyroid cancer.
Page 859
Imaging tumor status in prostate cancer: al Jalali and colleagues explore the use of [68Ga]PSMA and [18F]FDHT in PET imaging as a potential substitute for analysis of prostate cancer tumors, particularly in evaluating androgen receptor expression.
Page 863
Patient-reported outcomes for PC: Gudenkauf and colleagues detail development of a patient-reported outcome measure for radionuclide therapy in prostate cancer, with utility as a standardized tool to monitor relevant symptoms and toxicities.
Page 869
Signaling network response to TAT: Qin and colleagues investigate cellular responses to targeted α-particle therapy and demonstrate the radiosensitizing potential of histone deacetylase inhibitors for 225Ac-PP-F11N in cholecystokinin B receptor–positive tumors.
Page 873
PRRT in high liver tumor burden: Gococo-Benore and colleagues assess the risk of hepatotoxicity for patients with gastroenteropancreatic neuroendocrine tumors and very high liver tumor burden undergoing peptide-receptor radionuclide therapy.
Page 880
124I-MIBG dosimetry-guided 131I-MIBG therapy: Maric and colleagues report on the efficacy and safety of 124I-MIBG dosimetry-guided high-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or neuroblastoma.
Page 885
PSMA dosimetry in HGG: Graef and colleagues investigate [177Lu]Lu-PSMA therapy in high-grade glioma, with a focus on intratherapeutic dosimetry.
Page 892
PSMA PET/CT criteria and prognosis: Lunger and colleagues explore the prognostic utility of conventional biochemical/imaging response criteria and 68Ga-PSMA11 PET-based criteria for overall survival in metastatic hormone-sensitive and castration-resistant prostate cancer treated with taxane-based chemotherapy.
Page 896
68Ga-PSMA PET for PB recurrence SRT: Sonni and colleagues use 68Ga-PSMA-11 PET/CT to evaluate patterns of prostate bed recurrence and guide salvage radiotherapy in prostate-specific antigen persistence or biochemical recurrence after radical prostatectomy.
Page 902
PSMA expression in CRPC: Calderoni and colleagues examine PSMA expression in patients with castration-resistant prostate cancer and compare PET/CT response with prostate-specific antigen variation as a prognostic factor for progression-free and overall survival.
Page 910
PSMA-positive LNs and ENRT templates: Trapp and colleagues analyze PSMA PET/CT–positive lymph nodes and compare results with those from several templates proposed for salvage elective nodal radiotherapy, emphasizing the role of imaging in individualization of treatment.
Page 918
[225Ac]Ac-ofatumumab and lymphoma: Longtine et and colleagues describe preparation of 225Ac-labeled anti-CD20 ofatumumab and evaluate its in vitro characteristics and therapeutic efficacy in a murine model of disseminated human lymphoma.
Page 924
Strain analysis from ECG-gated PET MPI: Huang and colleagues detail development of a measure of longitudinal, radial, and circumferential myocardial strain at rest and during pharmacologic stress using 82Rb PET electrocardiography-gated myocardial perfusion imaging.
Page 932
PET and pulmonary fibrosis: Isser and colleagues use a 64Cu-labeled platelet glycoprotein VI fusion protein targeting extracellular matrix fibers as a PET tracer to observe longitudinal remodeling in a bleomycin-induced pulmonary fibrosis mouse model.
Page 940
Pretreatment 131I-omburtamab imaging and dosimetry: Pandit-Taskar and colleagues perform 131I-omburtamab imaging and dosimetric analysis for estimation of absorbed dose to the cerebrospinal fluid compartment before 131I-omburtamab therapy for leptomeningeal disease.
Page 946
AI-denoised low-dose 64Cu-DOTATATE PET: Loft and colleagues ask whether artificial intelligence approaches can be used to restore visual quality and lesion detection in PET images acquired with <50 MBq of 64Cu-DOTATATE in patients with neuroendocrine neoplasms.
Page 951
Total-body 68Ga-FAPI parametric imaging: Chen and colleagues explore the pharmacokinetics of 68Ga-FAPI-04 PET/CT in pancreatic and gastric cancer and conduct parametric imaging of dynamic total-body data compared with SUV-based imaging.
Page 960
Perfusion index with [18F]MK6240: Guehl and colleagues research the potential utility of the early phase of imaging with [18F]MK6240, with high affinity and selectivity for hyperphosphorylated tau, as a surrogate index of cerebral perfusion.
Page 968
Explainable AI: Bradshaw and colleagues summarize key arguments for and against the use of “explainable artificial intelligence” from the perspectives of data science, clinical practice, and bioethics.
Page 976
Ultrahigh-resolution small-animal PET: Kang and colleagues report on an ultrahigh-resolution small-animal PET scanner that can provide a resolution approaching 0.6 mm to visualize mouse brain function and serve as a promising molecular imaging tool for neuroscience research.
Page 978
Theranostic radiopharmaceuticals: Urbain and colleagues review currently available education and accreditation offerings and policies for theranostics around the world and discuss educational and proficiency challenges.
Page 986
68Ga-FAPI-46 urachal remnant: Maliha and colleagues present an example of potentially confounding incidental uptake in a urachal remnant on preoperative 68Ga-FAPI-46 PET/CT.
Page 992
Incidental bronchial findings on 18F-PSMA PET/CT: Orciuolo and colleagues describe a case of large-airway PSMA localization in a patient with chronic airway inflammation, highlighting the potential for false-positive findings.
Page 993
- © 2023 by the Society of Nuclear Medicine and Molecular Imaging.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.